A unique line of research
As early as the year 2000, Professor Yoram Palti, founder and emeritus professor of physiology and biophysics at the Israel Institute of Technology, explored the potential of electric fields to develop a new method of treating solid tumors without systemic effects. The research center, opened in 2002, paves the way for a first pilot study in newly diagnosed glioblastoma. With Novocure, Prof. Yoram Palti intends to offer patients a new cancer treatment that targets tumor cells without affecting healthy tissue, by disrupting cancer cell division. Called Tumor Treatment Camps, this treatment is a different approach to current cancer therapy. With a team of more than 1,300 employees and a headquarters in Switzerland, the international company has offices in Germany, Japan and Israel, and created its French subsidiary at the beginning of 2020.
A patient-centered approach
Based on fundamental physics, the Optune® medical device aims to treat very aggressive cancers such as glioblastoma, a brain tumor. The publication of the results of the pivotal clinical trial in 2017 and the approval of the CE mark in Europe and later the FDA in the United States have allowed the management of glioblastoma in 7 countries to date. With more than 27,000 patients treated worldwide, the company is committed to supporting patients through highly innovative technology but also through highly targeted technical support. In France, Novocure technical teams provide this service at home to train and support patients in the use of the device throughout their treatment.
The year 2023 marks a turning point for Novocure with both geographic and clinical development: in addition to its opening to new countries, several late-stage phase 3 trials in other aggressive solid tumors, as well as other earlier phase trials.
This content was produced in association with OpenMedias. The BFM Business editorial team was not involved in the production of this content.
Source: BFM TV
